Corixa Sells Bexxar Rights To GSK As Part Of Restructuring
This article was originally published in The Pink Sheet Daily
Executive Summary
The cost-cutting effort includes the elimination of 160 positions at the company's South San Francisco and Seattle operations, Corixa says. Copromotion partner GlaxoSmithKline will take over Bexxar development and marketing responsibilities effective Dec. 31.